

*Not for release, directly or indirectly, in South Africa, Australia, Canada, Japan, New Zealand or the United States of America*



## PRESS RELEASE

### STALLERGENES SHAREHOLDERS APPROVE THE PROJECT TO COMBINE THE ACTIVITIES OF THE GROUP AND GREER LABORATORIES

*The creation of the world leader<sup>1</sup>  
in allergy immunotherapy is underway*

**Antony, France, 26 June 2015** – At the General Meeting which took place today, 26 June 2015, STALLERGENES' shareholders were asked to vote, among other things, on the transaction to combine the activities of STALLERGENES and GREER Laboratories.

At the extraordinary general meeting, STALLERGENES shareholders approved this project, the purpose of which is to create the global leader in allergy immunotherapy. This favourable vote means that the transaction initially announced on 3 March 2015 can move into the next phase of completion.

In addition, on 19 June 2015, the Direction Générale des Finances Publiques (French tax authorities) has given its agreement in principle for the ruling required to allow the transaction to be entitled to the benefit of the special merger tax regime.

According to the current timetable, the transaction could take effect in September 2015, following completion of all legal formalities required for implementation.

Following completion of the transaction, STALLERGENES' and GREER's activities will be held by Ares Allergy Holdings PLC, the UK subsidiary of Ares Life Sciences. Listing of the new Group on the regulated Euronext market (under the name Ares Allergy Holdings PLC) is also expected to take place in September 2015 as soon as all the conditions precedent have been met.

Patrick Langlois, Chairman of STALLERGENES' Board of Directors, stated,  
*"The approval of this transaction by STALLERGENES' shareholders gives the green light for the creation of a new group, the world leader in allergy immunotherapy, an area undergoing significant growth and with huge development potential in key pharmaceutical markets."*

---

<sup>1</sup> Estimate based on internal sources.

## ABOUT STALLERGENES

STALLERGENES is a global healthcare company specialized in the diagnosis and treatment of allergies. For more than 50 years, STALLERGENES has been continuously expanding the existing frontiers of science in order to provide allergy patients with ever more effective long lasting therapeutic options. Thanks to its innovation strategy, fuelled by investments in research and development amounting to around 20% of total annual revenues as well as external partnerships, STALLERGENES is able to provide targeted allergen immunotherapy-based allergy solutions that significantly improve the lives of allergy patients around the world.

STALLERGENES operates in 23 countries and employs over 1,000 people. In 2014, the Company generated total revenues of €251 million, and more than 500,000 patients were treated with STALLERGENES products.

EURONEXT Paris (Compartment B)  
CAC small  
ISIN: FR0000065674  
Reuters: GEN.PA  
Bloomberg: GEN.FP



### **Forward-looking statements related to STALLERGENES**

*This press release may contain forward-looking statements concerning the proposed combination and the benefits expected. Such statements are based upon the current beliefs and expectations of Stallergenes' management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.*

### **Limitations**

*This document may not be released, directly or indirectly, in South Africa, Australia, Canada, Japan, New Zealand or the United States of America. The information contained in this document does not constitute an offer to sell or to purchase or the solicitation of an offer to purchase or sell shares or other financial instruments in Ares Allergy Holding or Stallergenes in the United States of America or any other jurisdiction in which such an offer, solicitation, purchase or sale would be unlawful prior to the registration, exemption from registration or other qualification under the terms of legislation on financial instruments in such a jurisdiction. Shares in Ares Allergy Holding have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under any other legislation of any jurisdiction in the United States of America and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act. There will not be any public offering of securities in the United States. Persons in possession of this document are required to inform themselves about and comply with these restrictions. Neither Stallergenes, nor Ares Allergy Holding or any other party to this transaction mentioned in this document accepts any liability in respect of persons who have obtained this document in violation of these restrictions.*

### **Contacts:**

Christian Chavy, Chief Executive Officer  
Tel. +33 1 55 59 20 04

### **Investor and analyst relations**

Peter Bühler  
Chief Financial Officer  
Tel: +33 1 55 59 23 22  
Email: investorrelations@stallergenes.com

### **Press relations**

Lise Lemonnier  
Senior Communication & Public Affairs Director  
Tel: + 33 1 55 59 20 96  
Email: llemonnier@stallergenes.com

### **Investor and press relations agency:**

#### **Press:**

FTI Consulting – Analyst and investor contact  
Stephan Dubosq  
Tel: +33 1 47 03 68 16  
Email: stephan.dubosq@fticonsulting.com

FTI Consulting – Press contact

Anna Adlewska  
Tel: +33 1 47 03 68 63  
Email: anna.adlewska@fticonsulting.com